CONFIDENTIAL INVESTMENT PRESENTATION www Vivione Biosciences com Symbol

CONFIDENTIAL INVESTMENT PRESENTATION www. Vivione. Biosciences. com Symbol “VBI” (TSX Venture Exchange) 1

FORWARD-LOOKING STATEMENTS Some of the statements contained herein including, without limitation, financial and business prospects and financial outlooks, may be forward-looking statements that reflect management’s expectations regarding future plans and intentions, growth, results of operations, performance, and business prospects and opportunities. Words such as “may, ” “will, ” “should, ” “could, ” “anticipate, ” “believe, ” “expect, ” “intend, ” “plan, ” “potential, ” “continue, ” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on uncertainties. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements including changes in general economic and market conditions and other risk factors. Although the forward-looking statements contained within this presentation are based upon what management believes to be reasonable assumptions, management cannot assure that actual results will be consistent with these forward-looking statements. Investors should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and we assume no obligation to update or revise them to reflect new events or circumstances. 2

Company Overview • Vivione Biosciences is a technology and life sciences company focused on rapid bacterial detection • The company has developed a proprietary diagnostic system called RAPID-B, which tests bacteria in critical environments and provides quantitative results in seven hours or less • We believe that RAPID-B is the fastest, most accurate, and most cost-effective diagnostic testing system currently available for detecting bacteria • Vivione is in the process of commercializing the RAPID-B system for several multi-billion dollar markets, including clinical in-vitro diagnostics, oil & gas, and food safety 3

COMPANY BACKGROUND • Vivione Biosciences was founded in 2006 under a Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration • RAPID-B was developed in collaboration with the FDA’s National Center for Toxicological Research • Vivione and the FDA have jointly filing patent applications • Vivione has received exclusive licensing rights from the FDA • Vivione Biosciences became a public entity in April 2013 through a Capital Pool Company (CPC) merger – Raised $6 million concurrently with the merger – Currently listed on TSX-V • Headquartered in Dallas, Texas – with world class labs in Little Rock, Arkansas 4

Investment Highlights • Vivione has been gaining traction in the Oil & Gas market – and is currently negotiating approximately $5 mm in purchase orders – Quotes already sent to several Fortune 500 companies • Vivione is currently launching clinical pilot studies at the Cleveland Clinic and Northwestern University • Vivione is seeking to acquire Trillium Diagnostics – a company focused on discovering and commercializing novel cellular biomarkers used in flow cytometric analysis. • The Trillium acquisition will be immediately accretive - and will add revenues, IP, and customers within the clinical diagnostic market 5

THE RAPID-B SYSTEM Flow -> Sample Real-time Software Processing Sheath Fluid Flow Cytometer 2 Laser plus six Photo Multipliers Sized-based Detection Viability Screen of the Target Specific Target Detection RAPID-B Instrument 1 -Minute Analysis Finding bacteria in a sample is akin to finding a needle in a haystack. The RAPID-B technology analyzes every ‘needle’ superfast - to find the bacteria of interest. 6

RAPID-B: SYSTEM HIGHLIGHTS RAPID-B’s Flow Cytometric system produces faster, more precise, and more cost-effective diagnostic results • PROPRIETARY: Joint patents filed with the FDA, exclusive licenses with the FDA • SPEED: Generates results in substantially less time than competing technologies – 15 min to 8 hrs (RAPID-B) vs. 24 hrs to 28 days (Competitors) RAPID-B System Hardware Software + • ACCURATE: Capable of counting the exact number of bacteria cells – providing greater accuracy and sensitivity. Can detect both live and dead cells - minimizing false results • RUGGED: Durable and easily operated by lab personnel in the field • COST EFFECTIVE: Saves customers money through improved efficiencies, reduced chemical costs, and longer-lasting equipment Wetware 7

RAPID-B: TARGET MARKETS The RAPID-B system provides rapid bacteria detection in multiple markets 1. Clinical Market Applications – commercialization in 2015 2. Oil & Gas - commercialized in 2014 3. Food Processing and Distribution - commercialized in 2014 8

Market Opportunity: Clinical Diagnostics Addressable Market: • $12 billion global microbiology market (approx $6 BB U. S. market) • $3 BB global sepsis market Target Customers: • Hospitals and clinics • Large commercial Labs Product opportunities: • More than 20 million blood cultures ordered in U. S. annually • Average number of blood/urine tests performed per ICU: 100 per day (3, 000 per month) RAPID-B Benefits: • Able to detect bacteria in blood and urine within hours (vs. days) - providing the physician with the information necessary to prescribe the proper antibiotic, and potentially saving lives and reducing patient’s stay in the hospital • Cost-effective screening method to determine which antibiotic is most effective • Trillium’s patent on CD 64 allows physicians to diagnose the probability of a patient becoming septic faster than the current Procalcytonin test. • Successful completion of UTI pilot study at Cleveland Clinic (100% sensitivity/85% specificity at 15 minutes vs 48 hrs) Certification: • FDA Certifications required (Trillium acquisition will provide CE mark) 9

CLINICAL COMPETITIVE ADVANTAGES Current Method Time to Results Vivione Advantage Blood Culture Screen CO 2 detection (Bio. Mérieux, BD, Trek) 18 -72 hours Speed to result Flow(3 -5 hours) - cytometric Quantification Urine Culture Screen Gram stain, Culture plate, Sysmex 24 -72 hours Flow. Speed to result (3 -6 cytometric hours) - Quantification Pneumonia Etiology Gram stain, Culture plate 48 -72 hours Speed to result (2 -4 Flowhours) - Sensitivity & cytometric Specificity Sepsis Etiology Molecular methods (Roche, BD, Cepheid) Culture methods 20 -72 hours Flow. Speed to result (3 -5 cytometric hours) - Quantification 10

DRUG SUSCEPTIBILITY Direct Analysis Drug Susceptibility Analysis Time to Results Parameters Assessed Broth Dilution 12 -18 hours Turbidity e. Test Bio. Mérieux 12 -18 hours Plate Inhibition Current Methods Disk Diffusion 16 -24 hours Plate Inhibition Automated, Bio. Mérieux, BD, Siemens 3. 5 -24 hours Growth Density Vivione Time to Results 1. 5 to 2 hours Vivione Parameters Assessed Both Growth and Morphology 11

ACQUISITION: TRILLIUM DIAGNOSTICS Trillium is a diagnostic development company focused on discovering and commercializing novel cellular biomarkers to be used in flow cytometric analysis. Trillium’s lab is located in Bangor, ME and the company currently has 5 employees. Trillium’s approach has several advantages over traditional blood biomarkers: 1. 2. What cells are expressing the biomarker which can add a high level of sensitivity to the disease diagnosis. How much of the biomarker is expressed. Trillium's core products are: 1. 2. 3. Leuko 64 (sepsis and therapeutic response in septic patients) CD 163 (inflammation) Fetaltrol (reagent used to assess maternal-fetal hemorrhage) Vivione has presented Definitive Documents and has exclusivity through December 31, 2014, with the ability to extend for an additional 30 days. Completion of acquisition is contingent upon signing of Definitive Documents and Funding. 12

TRILLIUM ACQUISITION: BENEFITS Benefits of the Trillium Diagnostics acquisition include: • Adds revenue immediately • $1 mm in 2014 • $3. 1 mm in 2015 (est. ) • Adds intellectual property • CD 64 test has already received CE Mark (Europe’s equivalent to FDA approval), which provides immediate access to the European clinical market • FDA De Novo application in process • Over 20+ white papers showing CD 64 is more sensitive/accurate than current market leader – Procalcytonin ($100 MM +/Year Revenue) • Adds deep experience • Trillium’s staff has over 30 years extensive experience in both research and clinical practice with laboratory hematology and diagnostic flow cytometry • Dr. Bruce Davis is an industry expert in flow cytometry and will assume CSO role at Vivione 13

TRILLIUM ACQUISITION: TERMS Vivione will acquire 100% of Trillium debt-free through cash and stock purchase Approximately 60% of consideration is based on milestone achievement Cash portion: • $1, 500, 000 cash at Closing • $500, 000 cash earnout if Trillium achieves $1 mm in revenue in 2014 • $1, 000 cash earnout if Trillium obtains FDA approval for CD 64 by June 30, 2015 Stock portion: • $4, 000 in stock at Closing (minimum of $. 35 per share) • $8, 000 in stock as earnout based on achieving certain FDA approvals (At market or $. 35 minimum) 14

Market Opportunity: Oil & Gas Addressable Market: • $2. 9 billion worldwide ($1. 3 billion U. S. only) Target Customers: • Oilfield Services companies (i. e. Hydraulic Fracturing, Water Treatment) • Oil & Gas producers Current Customers: • Apache Energy purchased RAPID B Unit • Trican, Green Energy purchased WCT and BET services Product opportunities: • Fracing uses large volumes of water supplied from numerous sources, which must be tested repeatedly for the presence of bacteria • Biocides are often used to treat contamination of water, fluids, and wells and require repeated testing in order to confirm the elimination of bacteria • Typical frac company performs 240 -400 bacteria tests per month (4 frac jobs per month, 60 -100 tests per job) • Custom-Developed Reagents to identify sulphur-reducing bacteria (SRB) and acid-producing bacteria (APB) RAPID-B Benefits: • Quickly and accurately identifies bacterial contamination that can cause scale formation, pitting of steel, stress cracks – which ultimately reduce the production capability of wells • Enables companies to test fluid samples on location - providing valuable results in minutes (vs. days) and allowing for immediate fluid remediation • Optimizes biocide utilization 15

Oil & Gas Competition Current Method ATP (LUMINULTRA) Total Bacteria Count Sulphur Reducing Bacteria (SRB) q. PCR (Bi. SN; ALS) Time to Results Advantage Flow-cytometric Speed to result - (≤ 20 minutes)- Quantification Flow-cytometric (UNDER DEVELOPMENT) Speed to result (Estimated ≤ 2 hours) – Speciation & Quantification ≤ 60 minutes ≤ 3 Days GHB MPN Bug Bottles (Biotechnology Solutions; BTI) ≤ 20 Days MPN Bug Bottles (Biotechnology Solutions; BTI) ≤ 28 Days q. PCR (Bi. SN; ALS) Vivione ≤ 3 Days Lateral Flow (Modern Water; ≤ 30 minutes Bactiquant) MPN Bug Bottles ≤ 20 Days (Biotechnology Solutions; BTI) Acid Producing Bacteria (APB) Well Characterization Test q. PCR (Bi. SN; ALS) ≤ 3 Days Molecular methods (Bi. SN; Taxon Biosciences; GENEWIZ Metanome; Ubiome; Seq. Matic) 14 -90 Days Molecular methods Speed to result (≤ 7 Days) 16

Vivione Management Team Kevin Kuykendall - Chairman and Chief Executive Office Mr. Kuykendall has more than 20+ years in senior management positions for Fortune 100 to early stage companies and has experience in fund raising and operations. Mr. Kuykendall is currently CEO of Vivione Biosciences, Inc. and was instrumental in taking the company public on the Toronto Stock Exchange, raising $6 million, and commercializing the Company’s products in 2013. He was also a Founding Member and CEO of White Energy (Ethanol Producer) and Health 2 O (Nutraceutical). Mr. Kuykendall raised over $490 MM in equity/debt for White Energy and developed $750 MM in Revenue within the first 36 months of operations. Kevin played major league baseball for the Cleveland Indians and has a Bachelor of Science degree in Business Administration from Western Oregon University. Dr. Gombrich serves as Chief Medical Officer (CMO) has approximately 20 years of development experience in the In Vitro diagnostic sector, namely around infectious disease and cancer testing. Dr. Gombrich was instrumental in market development of several rapid diagnostic assays for pneumonia-related pathogens, including the Binax (Alere) Rapid Legionella Assay and Pneumococcal Urinary Antigen tests. This included postmarket clinical study design and the creation of sales and marketing educational content. Dr. Gombrich also has been involved in product development of a point-of-care cervical cancer screening test aimed at the developing world. Dr. Gombrich received his Medical Degree and Masters degree in Experimental Pathology from Case Western Reserve University in Cleveland in 2005. Chester J. Jachimiec, serves as the Chief Financial Officer (CFO) of the Company. Mr. Jachimiec has over 30 years of experience in law, public accounting, finance, corporate development and product commercialization in the technology and energy industries. He has been a founder, and involved in the capitalization and growth of several public and private companies in the facilities services, fuels and lubricants distribution, oilfield services, software and bio-diagnostics industries. Mr. Jachimiec was an initial founding shareholder and director of PACEpartners Inc. , the predecessor by merger of the Company. Mr. Jachimiec holds a Bachelors of Business Administration in Accounting from Loyola University of Chicago and a Juris Doctorate from Northwestern University School of Law. 17

Vivione Senior Management (Cont’d) Dr Bruce H Davis will serve Chief Science Officer (CSO) upon closing of the Trillium transaction and is a recognized international leader in the fields of laboratory hematology and diagnostic flow cytometry. He has had over thirty-five years experience in academic medicine following receiving his M. D. and B. S. degrees from University of Connecticut and Cornell University (pathology faculty at SUNY Upstate Medical Center, Dartmouth-Hitchcock Medical Center and Wm Beaumont Medical Center). Dr Davis has been active in laboratory standardization (Past Chair CLSI Hematology Committee, CAP Hematology Resource committee for 10+ years, and past Treasurer and board member for International Council for Standardization of Haematology; lead author of several practice guidelines and consensus guidelines in clinical cytometry), leadership in diagnostic medicine (co-founder, Internal Society for Laboratory Hematology; recipient of Bernd Houwen Award from ISLH; past-President, charter board member and recipient Wallace Coulter Award , International Clinical Cytometry Society; Mentor of Year award, CLSI), and as an innovator within the in vitro diagnostic field (founder and president, Trillium Diagnostics, recipient of 2007 Innovator of the Year from Maine International Trade Center and 2009 Frost & Sullivan's European IVD Innovator of the Year Award). He has over 100 peer-reviewed publications is currently focused on the establishment in clinical practice of the patented innovative biomarkers (neutrophil CD 64 expression, soluble CD 163 levels, and cf. DNA quantitation in blood) in the area of infection/sepsis detection and clinical monitoring, while continuing to improve maternal healthcare with superior IVD tools for monitoring fetomaternal hemorrhage. Dr Davis is currently working full time in the IVD diagnostic field through Trillium Diagnostics after over 25 years in medical practice as a board certified hematopathologist in both academia and large esoteric testing national laboratories. Mr. Springfield serves as the Senior Vice President of Sales and Marketing and has over 15 years of Marketing and Sales experience in the Clinical realm. Mr. Springfield’s leadership has been instrumental in the growth and success of early stage companies by penetrating and growing multimillion-dollar accounts and driving top line revenue and bottom line profit growth. He has responsibility for the company's Global Marketing and Sales groups. His organization is responsible for positioning Vivione's growth strategy, cultivating opportunities in new and existing customer markets and growing demand for Vivione's solutions globally, as Vivione establishes itself as the #1 Rapid Diagnostics company in the world. Ms. Bradford serves as Director of Sales and Marketing for Vivione and has over 15 years’ experience in Sales and Marketing, Product Development and Manufacturing in the Clinical and Nutraceutical sector. As a Certified Nutritionist, Pharmacy Technician and Health and Fitness writer she combines her knowledge of nutrition, pharmaceuticals and health conditions with her innate ability for strategic business planning to create and execute sales strategies for companies looking to expand their product offerings and portfolio. Ms. Bradford has received industry awards for Best Practices in developing sustaining business models that significantly and consistently drive revenue. Her strategic know-how blended with the right amount of thought leadership has enabled her to build a sales model that connects a variety of industries including clinical, nutraceutical, food safety and oil and gas. 18

THE OFFERING CAN $10, 000 Vivione Biosciences, Inc. (VBI) a TSX Venture Exchange listed company headquartered in Little Rock, AR is offering up to 28, 571, 429 shares of stock* in the company at a price of $0. 35 per share Subject to TSX approval. Canadian residents shall receive Class A shares; non-Canadian residents shall receive Class B shares which are non-voting but are convertible into Class A shares on 75 days notice. Except for voting rights, Class B shares have the same rights and privileges of Class A shares prior to conversion. Said shares are NOT listed on the TS Venture Exchange. 19

USE OF FUNDS $10, 000 Total Investment $ 750, 000 Closing Costs (Finders Fee, legal, accounting) $1, 500, 000 Trillium Diagnostic Payment $ 350, 000 Stratedigm Equipment purchase $1, 000 Assay Development $2, 000 FDA 510 k Clinical studies (CD 64) $5, 600, 000 Total Business Costs $4, 400, 000 Working Capital Reserve $10, 000 Total Use of Funds 20

CAP TABLE (PRE- AND POST-FUNDING) Pre-Closing Capitalization Class A Voting Common Shares 37, 707, 086 Class B Non-Voting Common Shares 29, 387, 762 Options 5, 617, 190 Warrants 14, 752, 000 Post-Closing Capitalization (assumes max offering is reached) Class A Voting Common Shares 51, 992, 800 Class B Non-Voting Common Shares 43, 673, 476 Options 5, 617, 190 Warrants 14, 752, 000 Note: Assumes $10 MM Investment is 50/50 split between Class A/Class B shares for US Investors 21

COMPARABLE VALUATIONS Table of comparable bioscience companies and EV/Rev multiples (US$) Revenue Range Market Cap Multiple (EV/Rev) Status Relevance Accuri † $20 MM $205 M 10. 25 Sold - 09/2011 Diagnostics / Instrumentation Cepheid $446 -461 MM $3. 73 B 8. 09 -8. 36 NASDAQ (2/25/14) Microbiology Diagnostics Handylab ‡ $8 MM (est. ) $275 M 34. 38 Sold - 11/2009 Microbiology Diagnostics MTM ‡‡ $15 MM (est. ) $180 M+ 12. 00 Sold - 07/2011 Diagnostics Neogen $235– 250 MM $1. 59 B 6. 36 -6. 77 NASDAQ (2/25/14) Microbiology Diagnostics $3. 4 MM $215 M 62 NASDAQ (8/22/14) Microbiology Diagnostics $490 M* 5. 45 Company Roka BRAHMS $90 MM Sold-2008 Biomarker Discovery (Procalcitronin) † BD Bioscience Acquisition ‡ BD Biosciences Acquisition ‡‡ Roche's-Ventana Medical Systems Acquisition * Acquired by Fisher 2008 22

Investment Summary • Vivione Biosciences is a technology and life sciences company focused on rapid bacterial detection with an expanding IP portfolio • The company’s RAPID-B platform is the fastest, most accurate, and most cost-effective diagnostic testing system currently available for detecting bacteria • Vivione is in the process of commercializing the RAPID-B system for several multi-billion dollars markets, including oil & gas, food safety, and clinical in-vitro diagnostics • Vivione has completed a clinical pilot studies at the Cleveland Clinic and preparing for a study at Northwestern University • The Trillium acquisition will immediately add revenue, IP, experience management, and access to the clinical diagnostics market • The company has been gaining traction within the Oil & Gas market – and is currently negotiating $5 mm in purchase orders 23